Vice President, Lifecycle Leader, Daraxonrasib – Lung Cancer

The Opportunity:

Revolution Medicines is seeking a strategic, enterprise-minded Lifecycle Leader to lead the global lifecycle strategy for the daraxonrasib Lung Cancer program. This role is accountable for shaping and executing an integrated end-to-end molecule strategy — from pivotal development through commercialization and post-launch expansion — to maximize long-term patient and enterprise value.

The Lifecycle Leader serves as the cross-functional integrator and strategic architect for daraxonrasib, aligning disease area priorities, development strategy, regulatory considerations, and commercialization planning into a unified global roadmap. This individual will lead the cross-functional Lifecycle Team, drive strategic trade-offs within a portfolio context, and ensure seamless execution across geographies and functions.

The role requires deep commercialization expertise, including demonstrated NME launch leadership in oncology, and the ability to translate scientific progress into differentiated, launch-ready strategies that deliver meaningful impact for patients and sustained value for the organization.

Key Responsibilities

Lifecycle & Commercial Strategy

• Define and continuously refine the global lifecycle strategy for daraxonrasib across indications, lines of therapy, and combination opportunities.

• Identify cross-indication synergies, expansion pathways, and systemic program risks, drive mitigation strategies.

• Translate clinical data, competitive insights, and regulatory strategy into differentiated commercial positioning and value propositions.

• Ensure alignment between disease area strategy and molecule-level priorities.

Cross-Functional Integration

• Architect and lead the Lifecycle Team (LCT) and working groups in a fit-for-purpose manner.

• Partner closely with Clinical Development, Regulatory, Medical Affairs, Market Access, and Portfolio teams to ensure integrated decision-making.

• Serve as a core member of governance forums, preparing recommendations and driving enterprise alignment.

• Escalate major strategic decisions with clearly articulated recommendations aligned with portfolio principles.

Portfolio & Financial Stewardship

• Develop and own the strategic roadmap, milestones, financial targets, and key objectives of the asset.

• Balance long-term strategic priorities with short-term operational execution.

Organizational Leadership 

• Build, lead, and develop a high-performing, highly cross-functional lifecycle team, driving alignment and accountability across team members, senior leaders and functions to execute an integrated global lifecycle strategy.

• Contribute to the maturation and evolution of the Lifecycle function by establishing scalable frameworks, best practices, and operating models that enable integrated, end-to-end asset strategy across the portfolio

• Foster a collaborative, cross-functional culture that embraces innovation, agility, and accountability.

• Serve as a trusted advisor to executive leadership on lifecycle optimization and commercial value creation.

Required Skills, Experience and Education: 

• Bachelor’s degree required, MBA or advanced degree preferred.

• 15+ years of progressive biopharmaceutical experience, with significant oncology commercialization leadership.

• Demonstrated success leading at least one global NME launch in oncology.

• Deep expertise in lifecycle management, brand strategy, global marketing, and market access.

• Proven experience operating in multifunctional, high-pressure environments with ambitious milestones.

• Strong executive presence and ability to influence senior stakeholders.

Preferred Skills: 

• Experience in RAS-driven or precision oncology markets.

• Experience expanding assets across multiple lines of therapy and disease area settings.

• Prior experience in a rapidly growing biotechnology company.

• Global launch experience across U.S. and EU markets.